Летирам (Levetiracetam) is a prescription medication utilized in the management of epilepsy. It is intended to help address certain types of seizure activity in adults and pediatric patients.

Quick Facts: Therapeutic Domains

• Partial-Onset Seizures: Used as a single agent (monotherapy) in newly diagnosed adolescents and adults, or as supplemental therapy (adjunctive) for patients with epilepsy, including infants and children.
• Myoclonic Seizures: Utilized as an add-on treatment for myoclonic seizures in individuals with Juvenile Myoclonic Epilepsy.
• Primary Generalized Tonic-Clonic Seizures: Employed as supplemental treatment for these major seizure types in patients with Idiopathic Generalized Epilepsy.

This medication is a component of a comprehensive treatment plan for seizure control. The specific therapeutic indications include approved age groups for monotherapy and adjunctive use.

Regulatory References

1. EMA therapeutic overview

Eligibility Scope

Populations for whom use is contraindicated:

Летирам is strictly contraindicated in any patient with a known hypersensitivity to the active substance, Levetiracetam, or to other pyrrolidine derivatives or any excipients contained in the specific formulation. This represents an absolute non-eligibility rule as defined in regulatory documents.

Age-related eligibility rules:

Eligibility is defined by specific age thresholds for different uses. Adults and adolescents 16 years and older are approved for most indications, including monotherapy. For adjunctive therapy, the medicine is approved for use in infants as young as one month for partial-onset seizures. The safety and efficacy of the medicine as monotherapy in children and adolescents under 16 years are not established.

Condition-specific eligibility rules:

Regulatory agencies require restricted or conditional use in certain populations. Levetiracetam clearance is reduced in all degrees of renal impairment, requiring a formal assessment of kidney function and a modified dosage regimen for safe use. An assessment of renal function is also generally recommended for older adults, who may have age-related decline in kidney function. In severe hepatic impairment, assessment of kidney function is advised before initial use.

Pregnancy and lactation eligibility status:

Use during pregnancy is permitted when clinically necessary, but drug plasma levels must be monitored closely due to physiological changes. The medicine is excreted into human milk, and use during lactation is generally not recommended by the manufacturer due to potential infant risk.

Interaction Map: Interactions with other medicines and products — official regulatory information for Levetiracetam

Interaction Scope

Medicinal product categories with documented interactions: Central Nervous System (CNS) depressants, alcohol, enzyme-inducing Antiepileptic Drugs (AEDs), laxatives (Macrogol).

Specific interacting medicines (if explicitly listed): Warfarin, Digoxin, Ethinyl Estradiol, Levonorgestrel, Carbamazepine, Phenytoin.

Mechanistic basis of interactions (only if stated in label): Pharmacodynamic interaction (additive CNS depression); Pharmacokinetic interaction (altered clearance due to renal function or enzyme induction). No inhibition or induction of major hepatic CYP450 enzymes is documented.

Timing-based interaction rules (if applicable): None are formally documented for separation windows; the medicine may be taken without regard to food.

Population-specific interaction notes (if applicable): Clearance is decreased in patients with renal impairment, which affects overall drug exposure. Plasma concentrations may also decrease during pregnancy.

Interaction-related restrictions: Co-administration with CNS depressants or alcohol is restricted by the expected additive pharmacodynamic effect (increased somnolence).

---

Interaction Classifications (high-level)

Interaction severity classification (as defined in official documents): No medicinal products are formally classified as contraindicated. Most are classified as non-significant pharmacokinetic or additive pharmacodynamic.

Regulatory basis (EMA / FDA / etc.): FDA Prescribing Information, EMA Summary of Product Characteristics.

Interaction-context constraints (as defined in official documents): Co-administration with enzyme-inducing AEDs results in altered (increased) clearance of Levetiracetam.

---

Resulting Interaction Structure

Official interaction statements:

• Co-administration with CNS depressants or alcohol is documented to result in an additive pharmacodynamic effect, increasing somnolence.
• Levetiracetam does not significantly affect the pharmacokinetics of oral contraceptives (Ethinyl Estradiol, Levonorgestrel), Warfarin, or Digoxin.
• Levetiracetam does not inhibit or induce the major human hepatic CYP450 isoenzymes.
• Clearance is decreased in patients with renal impairment, which is a key factor in managing drug exposure.
• The medicine can be taken without regard to food, as absorption is not altered.

Connection to the overall interaction profile (2–4 sentences): The official regulatory documents define Levetiracetam’s interaction structure primarily by its metabolic neutrality, confirming no substantial enzyme-mediated interference with most co-administered medicinal products. The key constraints relate to the additive CNS depression risk with substances like alcohol and the mandatory regulatory consideration of altered clearance in populations with renal impairment. This profile confirms the absence of formal contraindicated combinations based on documented interaction data in major government labels.

Летирам (Levetiracetam) primarily modulates the activity of electrical signaling within the central nervous system (CNS), resulting in altered physiological signaling patterns. Its mechanism is distinct from older agents and involves a unique set of targets that ultimately influences the frequency and synchrony of neuronal firing.

---

Targeting Synaptic Vesicle Protein 2A (SV2A)

This domain focuses on the primary mechanistic target of Летирам, the synaptic vesicle glycoprotein 2A (SV2A), a protein found on presynaptic vesicles in neurons. By engaging with SV2A, the drug modulates the release of neurotransmitters, diminishing the rate and magnitude of synchronized neuronal discharge. This interaction alters synaptic transmission and modifies the conditions leading to high-frequency neuronal synchronization.

---

Modulating Presynaptic Neurotransmitter Release

The direct interaction with SV2A triggers a downstream mechanistic cascade that leads to the inhibition of presynaptic calcium channels and a subsequent reduction in the release of excitatory neurotransmitters, such as glutamate. This modification of the release process for key chemical messengers in the synapse limits the propagation of high-amplitude electrical signals, influencing the signal-to-noise ratio within targeted neural networks.

How Летирам is Used: Administration Guidelines

Летирам (Levetiracetam) is used according to established guidelines for administration and dosing. This ensures standardized use across clinical practice.

---

Approved Routes and Forms

Летирам is available in multiple forms to allow for two approved routes of administration, suitable for both long-term and short-term use:

• Oral: Immediate-release tablets, extended-release tablets, and oral solution. Oral forms may be taken with or without food.
• Intravenous (IV): Concentrate for solution for infusion, generally reserved for temporary use when oral administration is not feasible. The IV solution must be diluted and administered as a 15-minute infusion.

Standard Dosing and Schedule

Treatment typically follows a gradual process of dose adjustment:

Administration Type	Dosing Frequency	Key Dosing Principle
Immediate-Release/IV	Twice Daily (Every 12 hours)	Starts low and is gradually increased (titrated) in increments over two-week intervals.
Extended-Release	Once Daily	Swallowed whole; must not be chewed, broken, or crushed.

Population-Specific Use

Specific adjustments are utilized for certain patient groups to maintain proper drug concentration:

• Renal Impairment: The dose is reduced based on the patient's measured creatinine clearance, including specific instructions for patients undergoing dialysis.
• Pediatric Patients: Dosing for children weighing less than 50 kg is determined using a weight-based (mg/kg) regimen.

Discontinuation Protocol

If the medication needs to be stopped, it is recommended that the dose be gradually decreased (tapered) over a period of weeks to minimize potential adverse consequences.

Research Evidence / Overview of Studies for Летирам (Levetiracetam)

---

Evidence for Use in Partial-Onset Seizures

Research has explored Летирам for conditions characterized by fluctuating or episodic manifestations such as partial-onset seizures, both when used alone (monotherapy, typically in newly diagnosed patients) and when added to an existing epilepsy medication (adjunctive therapy). These investigations primarily take the form of short-term Randomized Controlled Trials (RCTs), where results are compared against a placebo, alongside longer, open-label studies where all participants received the medication. Researchers focused on measuring outcomes related to systemic or functional imbalance, such as the proportion of participants who achieved seizure freedom and the percentage of individuals who saw their seizure frequency reduce by half or more (known as the responder rate).

These studies included a wide range of individuals, from adults and adolescents who were newly diagnosed to patients of various ages—including infants as young as one month—whose seizures involved periods of heightened symptoms despite prior use of other medicines. The studies reported measurements of changes in seizure frequency observed in these groups over the controlled trial period, which typically lasted 12 to 18 weeks.

Evidence for Use in Myoclonic Seizures

Летирам was evaluated in research focusing on myoclonic seizures, specifically when these seizures occurred in adolescents and adults with Juvenile Myoclonic Epilepsy (JME). These studies were mainly short-term RCTs, where the compound was studied as an add-on treatment. The primary measurements in these research scenarios focused on changes in the frequency of myoclonic seizures per week or month, and studies monitored the rate at which patients achieved a significant reduction in these episodes.

Evidence for Use in Primary Generalized Tonic-Clonic Seizures

The compound was studied for its role as an adjunctive treatment for primary generalized tonic-clonic (PGTC) seizures in individuals with Idiopathic Generalized Epilepsy (IGE). These investigations were conducted using short-term RCTs, typically lasting 16 to 24 weeks. Research examined outcomes related to episodic or acute changes, such as the change in the frequency of PGTC seizures and the time that passed before a patient experienced their first PGTC seizure recurrence during the trial period.

---

What Is Still Uncertain About Летирам

While extensive research has examined Летирам, certainty remains low when looking at the very long term, as most pivotal research was short-term. The full duration of outcomes is not fully established by the initial RCTs, and data for certain groups, such as older adults or individuals with specific comorbid conditions, remains insufficient compared to the primary adult and adolescent populations. Comparative evidence, particularly studies that directly compare Летирам against the latest alternative anti-epileptic medicines, is lacking in some contexts.

Common questions about Летирам (FAQ)

---

Q: What is the main difference between Летирам and similar drugs I see online?

Official information describes that the active ingredient, Levetiracetam, has a unique mechanism of action compared to many older medicines used for similar conditions. It primarily works by binding to a protein called SV2A in the brain. Furthermore, regulatory interaction maps show it has minimal drug-drug interactions because it is not significantly metabolized by the major liver enzyme system (CYP450).

---

Q: How quickly should I expect to notice any changes after starting Летирам?

Regulatory documents indicate that Летирам is rapidly absorbed after being taken orally. However, treatment typically involves a gradual process where the dose is slowly increased over two-week intervals. This titration process suggests the full expected therapeutic effect may be achieved over several weeks.

---

Q: If I miss a dose of Летирам, what is the official advice?

Official patient guidance for antiepileptic medicines often suggests taking the missed dose as soon as it is remembered. However, if the next dose is soon, official sources advise skipping the missed dose entirely. This is advised to prevent taking two doses too close together, which could be an excessive amount.

---

Q: Does Летирам interact with common pain relievers like ibuprofen?

Official drug interaction studies have not documented a significant interaction between Levetiracetam and common non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen. This is consistent with its low potential for pharmacokinetic interactions, meaning it does not interfere with the way most other medicines are processed by the body.

---

Q: Can Летирам affect my ability to drive or operate machinery?

Official regulatory warnings indicate that this medicine may cause drowsiness, dizziness, or affect coordination and reaction time. Driving or operating complex or heavy machinery should be avoided until an individual understands how the medicine affects their alertness.

---

Q: Why is Летирам sometimes prescribed long-term?

Летирам is indicated to help control the occurrence and severity of seizures associated with chronic conditions like epilepsy. According to official guidelines, control of these types of conditions typically requires continuous, long-term pharmacological therapy to maintain a stable electrical state in the brain.

---

Q: Is there a generic version of Летирам available?

Yes, the active substance in the medicine is called Levetiracetam, which is the generic (non-proprietary) name. Generic versions containing Levetiracetam are widely approved by regulatory bodies and available in various approved formulations.

---

Q: Does Летирам have a risk of dependence or addiction?

According to major government regulatory documents, Летирам is not classified as a controlled substance under the U.S. Controlled Substances Act or similar international schedules. This classification reflects a low potential for misuse, dependence, or addiction.

---

Q: Can I take Летирам if I am taking over-the-counter supplements?

Летирам has a low potential for pharmacokinetic drug interactions due to its minimal involvement with major liver enzymes. Specific over-the-counter supplements are not always listed in regulatory labels, so disclosure of all supplements to the prescribing physician is an important part of safety review.

---

Q: How long does Летирам typically stay in the system after the last use?

Official pharmacokinetic data indicates that the medicine has a mean elimination half-life of approximately seven hours in adults with normal kidney function. This means the concentration of the substance is substantially cleared from the body within a few days of the final dose.

---

Q: Can Летирам be taken with foods that contain caffeine?

Regulatory documents confirm that the medicine can be taken with or without food. However, official information advises caution because high amounts of caffeine, which is a stimulant, can lower the seizure threshold in some people and may counteract the intended effects of anti-epileptic medicines.

---

Q: What should I do if a minor side effect of Летирам is bothering me?

Regulatory documents and patient leaflets indicate that contact with a doctor or pharmacist is advised if a side effect is bothersome, persists, or causes concern. A healthcare professional can help discuss potential strategies for managing the effect or determine if an adjustment is appropriate.

---

Q: Why might a doctor switch a patient from an old medication to Летирам?

A healthcare provider may consider switching a patient based on Летирам's profile, including its unique mechanism of action that works differently from older anti-epileptic agents. Another factor is its favorable interaction profile, which is due to minimal liver enzyme involvement.

---

Q: How is Летирам's effect monitored by doctors?

For most patients, routine blood-level monitoring is not standard due to its predictable profile. However, official monitoring is recommended for specific populations, such as patients with kidney impairment or during pregnancy, to ensure appropriate drug concentration.

---

Q: What is the general expectation for the duration of Летирам's action after a dose?

Based on its pharmacokinetic profile and to maintain a consistent therapeutic concentration, the medicine is generally prescribed to be taken in two equally divided doses per day (twice daily).

---

Q: Is Летирам known to cause weight changes?

Weight changes are not listed among the most common adverse reactions documented in major regulatory labels. While some clinical analyses suggest the medicine is generally considered weight-neutral, any significant or unexpected change in weight should be brought to the attention of the patient's physician.

---

Q: If I'm taking multiple medications, how can I check for Летирам interactions?

Regulatory labels instruct that patients must inform their doctor and pharmacist of all co-administered prescription drugs, over-the-counter medicines, and supplements. This allows healthcare professionals to check the full, officially documented interaction profile against the patient's specific regimen.

---

Q: Why are there warnings about combining Летирам with certain herbal products?

Official documents caution that certain herbal products can have pharmacological activity, such as effects on the central nervous system or liver enzymes. Because of this, caution is advised for any concomitant use, as these effects could potentially impact Летирам's safety or efficacy.

---

Q: Does Летирам contain gluten or lactose?

The final medicinal product often contains lactose as an inactive ingredient (excipient) in tablet form. The presence of gluten is usually not specified, but reviewing the full list of inactive ingredients for the specific formulation in the official Patient Information Leaflet is the recommended way to confirm content.

---

Q: Are there known interactions between Летирам and cold/flu medications?

Many common cold and flu medications contain central nervous system (CNS) depressants, such as specific sedatives or antihistamines. Combining Летирам with any CNS depressant can lead to an additive risk of side effects like excessive drowsiness, dizziness, or impaired coordination.

---

Q: Are there any specific dietary restrictions while taking Летирам?

No. The official patient information, found in regulatory documents, states that the oral forms of the medicine may be taken with or without food.

---

Q: Is Летирам generally considered appropriate for elderly patients?

Use in older adults is permitted, but official regulatory documents emphasize that a dose adjustment may be necessary. This is due to the fact that Летирам is mainly eliminated by the kidneys, and renal function is often reduced in the elderly population.

---

Q: Is there any public research looking at Летирам and pregnancy outcomes?

Yes, data from prospective pregnancy registries have been published and are monitored by regulatory bodies. While the medicine is permitted when clinically necessary, close monitoring of drug plasma levels is required during pregnancy due to physiological changes.

---

Q: Is Летирам classified as a controlled substance in any countries?

No. Levetiracetam is classified as a prescription-only medicine in many countries and is specifically not scheduled as a controlled substance in the United States. This classification reflects a low potential for abuse or dependence.

---

Q: If I have mild liver problems, can I still use Летирам?

Official guidance indicates that use is permissible even with mild liver impairment. However, because Летирам is predominantly eliminated by the kidneys, an assessment of kidney function is generally advised before beginning treatment. Dose adjustments are mandatory only for renal impairment.

---

Q: Do studies suggest any long-term effects of using Летирам?

Regulatory documents note that most pivotal registration studies were short-term, typically lasting only a few months. As a result, official information states that uncertainty remains regarding the full, very long-term safety and efficacy profile, as these outcomes are not fully established by the initial controlled trials.

---

Q: Can Летирам be used by people with a history of depression?

The medicine is officially associated with a risk of mood and behavioral changes, including depression and suicidal thoughts. Official documents indicate that close monitoring by a healthcare professional is necessary for patients with a history of psychiatric disorders while taking the medication.

The storage and disposal of Levetiracetam (Летирам) must adhere strictly to regulatory requirements to maintain product integrity and safety.

Storage Requirements

• Temperature: Store at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). The maximum storage temperature should not exceed 30 C (86 F).
• Protection: Levetiracetam tablets must be protected from moisture. The injectable solution requires protection from light and must remain in its original carton until use.
• Container/Stability: The oral solution bottle must be kept tightly closed in the original container, with a labeled shelf life of up to four months after opening.
• Child Safety: All formulations must be stored out of the sight and reach of children.

Disposal Instructions

• Disposal Rule: The primary method for discarding unused or expired Levetiracetam is through an authorized drug take-back program.
• Household Disposal: If a take-back program is unavailable, the product must be mixed with an undesirable substance (like dirt or used coffee grounds), sealed in a container, and placed in household trash. It is explicitly instructed not to flush the medicine down the toilet or pour it into a drain.